Opinion
A new era of TTP treatment
Many questions remain following the FDA’s approval of caplacizumab, specifically, which patients should receive it. The high cost of the drug is...
Kristin S. Ricci, MD
Many questions remain following the FDA’s approval of caplacizumab, specifically, which patients should receive it. The high cost of the drug is...